Description: Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.
Home Page: www.theralase.com
TLT Technical Analysis
41 Hollinger Road
Toronto,
ON
M4B 3G4
Canada
Phone:
416 699 5273
Officers
| Name | Title |
|---|---|
| Dr. Arkady Mandel DSc., M.D., Ph.D. | Interim CEO, Chief Scientific Officer & Director |
| Ms. Kristina Hachey CPA | CFO & Director |
| Mr. David M. Groves B.A | Pres of World Trade Division |
| Mr. Roger John Dumoulin-White | Director of Bus. Devel. |
| Lori Leach | Marketing & Media Relations Consultant |
| Mr. Vaughn Wyant | Marketing & Media Relations Consultant |
| Dr. Terry Ruch DVM | Equine Medical Consultant |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 19.836 |
| Price-to-Sales TTM: | 69.5794 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |